Day One Biopharmaceuticals, Inc. (DAWN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 21.53 |
| Open | 21.53 |
| Day High | 21.53 |
| Day Low | 21.53 |
| 52-Week High | 21.53 |
| 52-Week Low | 5.64 |
| Volume | 0 |
| Average Volume | 4.01M |
| Market Cap | 2.22B |
| PE | -20.7 |
| EPS | -1.04 |
| Moving Average 50 Days | 18.21 |
| Moving Average 200 Days | 10.72 |
| Change | 0 |
Data not available
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
GlobeNewswire Inc.
Mar 06, 2026 1:30 PM GMT
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of approximately $2.5 billion SURESNE
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
GlobeNewswire Inc.
Feb 24, 2026 9:00 PM GMT
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Ther
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-